证券代码：688161 证券简称：威高骨科 公告编号：2026-0006 山东威高骨科材料股份有限公司 关于选举第四届董事会职工代表董事的公告 山东威高骨科材料股份有限公司（以下简称"公司"）于 2026 年 3 月 16 日召开了职工代表大会，经与会职工代表审议，同意选举孔建明先生（简历 详见附件）为公司第四届董事会职工代表董事，任期自本次职工代表大会审 议通过之日起至公司第四届董事会任期届满之日止。 孔建明先生当选公司职工代表董事后，公司第四届董事会中兼任高级管 理人员职务以及由职工代表担任的董事人数未超过公司董事总数的二分之 一，符合相关法律法规的要求。 特此公告。 山东威高骨科材料股份有限公司董事会 2026 年 3 月 17 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 附件： 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会任期 届满，根据《中华人民共和国公司法》《山东威高骨科材料股份有限公司章程》 等相关规定，公司第四届董事会由九名董事组成，其中一名职工代表董事将 由职工代表大会选举产生。 第四 ...

证券代码：688161 证券简称：威高骨科 公告编号：2026-007 山东威高骨科材料股份有限公司 关于完成公司董事会换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易 所科创板股票上市规则》（以下简称"《上市规则》"）《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等法律法规、规范性文件及《山东 威高骨科材料股份有限公司章程》（以下称"《公司章程》"）的相关规定，山东 威高骨科材料股份有限公司（以下简称"公司"）于 2026 年 3 月 16 日召开了职工 代表大会、2026 年第一次临时股东会，选举产生了公司第四届董事会，任期自 2026 年第一次临时股东会审议通过之日起三年。 2026 年 3 月 16 日，公司召开了第四届董事会第一次会议，选举产生了董事 长、董事会专门委员会委员，并聘任了高级管理人员、证券事务代表。公司董事 会的换届工作已经完成，现将相关情况公告如下： 一、董事 ...

北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2026 年第一次临时股东会的 法律意见书 法律意见书 致：山东威高骨科材料股份有限公司 二〇二六年三月 法律意见书 北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2026 年第一次临时股东会的 根据中国证监会发布的《上市公司股东会规则》（下称"《股东会规则》"） 的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受山东威高骨 科材料股份有限公司（下称"公司"）的委托，指派律师出席公司 2026 年第一次 临时股东会（下称"本次股东会"），并就本次股东会的召集和召开程序、召集人 资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 诚实信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准 确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并承担相应法律 ...

证券代码：688161 证券简称：威高骨科 公告编号：2026-009 山东威高骨科材料股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股东会由董事会召集，采用现场投票和网络投票相结合的方式召开，会 议由董事长陈敏女士主持，本次会议的召集、召开方式符合《公司法》、《证券法》、 《公司章程》的规定。 （五） 公司董事和董事会秘书的列席情况 二、 议案审议情况 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 3 月 16 日 （二） 股东会召开的地点：上海市闵行区方亭路 499 号威高云行智创园公司会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 45 | | --- | --- | | 普通股股东人数 | 45 | | 2、出席会议的股东所持有的表决权数量 | 333,803,915 | | 普通股股东所持有表决权 ...

证券代码：688161 证券简称：威高骨科 公告编号：2026-008 山东威高骨科材料股份有限公司 第四届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第四届董事会第一次 会议于 2026 年 3 月 16 日以现场及通讯相结合的方式召开。本次会议应出席董事 9 人，实际出席董事 9 人，会议由董事长陈敏女士主持，本次董事会会议的召集 和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的 规定，会议决议合法、有效。 二、董事会会议审议情况 公司董事会同意选举陈敏女士为第四届董事会董事长。 表决结果：9 票同意，0 票反对，0 票弃权。 2、审议通过《关于选举公司第四届董事会专门委员会委员的议案》 公司董事会同意选举陈敏女士、孙建国先生、刘洪渭先生为战略委员会委员， 陈敏女士为主任（召集人）；选举刘洪渭先生、张海燕女士、孙建国先生为审计 委员会委员，刘洪渭先生为主任（召集人）；选举孙建国先生、陈敏女士、张海 燕 ...

证券代码：688161 证券简称：威高骨科 山东威高骨科材料股份有限公司 2026 年第一次临时股东会 会议资料 二零二六年三月 山东威高骨科材料股份有限公司 2026 年第一次临时股东会会议资料 2026 年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证 会议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》 《山东威高骨科材料股份有限公司章程》等相关规定，山东威高骨科材料股份 有限公司（以下简称"公司"）特制定 2026 年第一次临时股东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议人员的身份进行必要的核对工作，请被核对者给予配合。 出席会议的股东及股东代理人须在会议召开前 30 分钟到会议现场办理签到 手续，并请按规定出示股票账户卡、身份证明文件或法人单位证明、授权委托 书等，经验证后领取会议资料，方可出席会议。 经公司审核，符合条件参加本次会议的股东、股东代理人、公司董事、高 级管理人员、聘任律师及董事会邀请的人员等可进入会场，公司有权拒绝不符 合条件的人员进入会场。 会议开始后，由会议主持人 ...

- The report introduces a comprehensive impact coefficient model to measure the influence of index rebalancing on individual stocks, particularly focusing on the March 2026 adjustments for key indices such as STAR 50, STAR-ChiNext 50, STAR 100, Dividend Low Volatility 100, and Beijing Stock Exchange 50[9][11][14] - The comprehensive impact coefficient is defined as follows: $ effect\_total_{s}=\sum_{i=1}^{n}\frac{wt\_chg_{s_{i}}\times fund\_size_{i}}{amount\_avg_{s_{i}}20} $ where: - $ wt\_chg_{s_{i}} $ represents the weight change of stock $ s $ in index $ i $ - $ fund\_size_{i} $ is the tracking scale of index $ i $ - $ amount\_avg_{s_{i}}20 $ is the average trading volume of stock $ s $ over the past 20 days[11] - The model evaluates the impact of passive trading caused by index rebalancing, emphasizing that larger indices with higher tracking scales (e.g., STAR 50 with 1489 billion RMB) generate more significant passive trading effects, creating potential investment opportunities for stocks added to these indices[13][14] - The report provides detailed calculations of the comprehensive impact coefficients for stocks with significant adjustments, identifying stocks like Jikang Technology (impact coefficient: 5.95), Zhongke Feice (impact coefficient: 1.73), and Taoli Bread (impact coefficient: 1.55) as having notable positive impacts due to their inclusion in indices such as Beijing Stock Exchange 50 and STAR 50[14][17] - Stocks removed from indices also exhibit negative impact coefficients, such as Weida Optoelectronics (-2.95), Jike Shares (-2.65), and Junshi Biosciences (-1.73), reflecting the adverse effects of exclusion from key indices[17]

Summary of Company and Industry Insights from Conference Call Company Overview - The company discussed is Weigao Orthopedics, which is part of the medical device industry, specifically focusing on orthopedic products. Key Financial Metrics - For the year 2025, the company expects to achieve a revenue of 1.539 billion yuan, representing a year-on-year growth of 5.95% [1] - The net profit attributable to shareholders is projected to be 267 million yuan, with a year-on-year increase of 19.17% [1] - The net profit excluding non-recurring items is anticipated to be 252 million yuan, reflecting a growth of 19.59% [1] - After adjusting for share-based payment expenses, the net profit is estimated at approximately 296 million yuan, indicating a growth of about 32.13% [1] - The net profit excluding non-recurring items, after adjustments, is expected to be around 281 million yuan, with a growth of approximately 33.34% [1] - In Q4 alone, the company forecasts a revenue of 433 million yuan, which is a year-on-year increase of 17.2% [1] - The net profit for Q4 is expected to be 59 million yuan, showing a stable year-on-year performance [1] Operational Insights - The main factors influencing operational performance include: 1. The smooth execution of volume-based procurement in orthopedics, leading to an increase in market share for domestic leading brands [1] Strategic Initiatives - The company is implementing adjustments in its sales model and organizational structure by establishing a profit center system within business units to enhance sales professionalism and market coverage [2] - There is a notable increase in business from key hospitals, driven by a focus on core surgical techniques and multi-product line collaboration, resulting in sustained growth in overall surgical volume and revenue [2] - The company is increasing its R&D investment to drive innovation in orthopedic biomaterials, intelligent devices, and minimally invasive consumables, while also improving the localization of raw materials and process enhancements to achieve quality improvements and cost reductions [2] - Additionally, the company is strengthening its digital infrastructure and fine-tuning supply chain management, which is contributing to improved operational efficiency and profitability [2]

Core Viewpoint - The company reported a preliminary financial performance for the year 2025, indicating growth in revenue and net profit, driven by strategic adjustments in sales and ongoing investment in research and development [1][3][4]. Financial Data and Indicators - The company achieved an operating revenue of 153,919.23 million RMB, representing a year-on-year increase of 5.95% [3]. - The net profit attributable to the parent company was 26,663.92 million RMB, up 19.17% from the previous year [3]. - The net profit after deducting non-recurring gains and losses was 25,218.28 million RMB, reflecting a growth of 19.59% [3]. - Excluding stock payment expenses, the adjusted net profit was approximately 29,564 million RMB, marking a growth of about 32.13% [3]. - Total assets at the end of the reporting period were 506,999.15 million RMB, a 2.46% increase from the beginning of the period [4]. - The equity attributable to the parent company was 414,357.79 million RMB, up 4.81% [4]. - The net asset per share attributable to the parent company was 10.36 RMB, also reflecting a 4.81% increase [4]. Operational Performance and Financial Condition - The company experienced stable execution of orthopedic bulk procurement, with leading domestic brands increasing their market share [5]. - Sales strategies were enhanced through adjustments in sales models and organizational structure, focusing on professional departments to boost profitability [5]. - The company segmented its product lines and improved the professional capabilities of its sales team, leading to increased clinical service precision and academic leadership [5]. - There was a notable increase in business from key hospitals and a focus on developing lower-tier markets and promoting innovative products, contributing to sustained growth in surgical volume and revenue [5]. - Continuous investment in R&D was maintained, particularly in orthopedic biomaterials, intelligent devices, and minimally invasive consumables, fostering innovation in new orthopedic products [5]. - The company also emphasized the localization of raw materials and improvements in R&D processes to enhance quality and reduce costs [5]. - Digital transformation efforts were made to improve supply chain efficiency and reduce costs through refined management practices, resulting in rapid net profit growth [6].

Core Viewpoint - Weigao Co., Ltd. reported a revenue of 1.539 billion RMB for the fiscal year 2025, reflecting a year-on-year growth of 5.95%, and a net profit attributable to shareholders of 267 million RMB, which is a 19.17% increase compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 1.539 billion RMB, representing a 5.95% year-on-year increase [1] - The net profit attributable to the parent company's shareholders was 267 million RMB, showing a growth of 19.17% year-on-year [1] - Basic earnings per share were reported at 0.67 RMB [1] Group 2: Sales and Market Strategy - The overall execution of orthopedic bulk procurement remained stable during the reporting period, with leading domestic brands increasing their market share [1] - The company is actively adjusting its sales model and organizational structure, focusing on a profit center system centered around specialized departments [1] - There is a focus on product line segmentation and enhanced management through sales divisions, improving the professional capabilities and focus of the sales team [1] - The company is emphasizing collaborative sales across key surgical procedures, resulting in significant growth in core hospital business and increased efforts in developing lower-tier markets and promoting innovative products [1]